Safety and immunogenicity of RTS,S/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a randomised, double-blind, controlled trial

The Lancet Infectious Diseases

Volumn 16, Issue 10, 2016, Pages 1134-1144

  Otieno, Lucas ^a   Oneko, Martina ^b   Otieno, Walter ^a   Abuodha, Joseph ^b   Owino, Emmanuel ^a   Odero, Chris ^b   Mendoza, Yolanda Guerra ^c   Andagalu, Ben ^a   Awino, Norbert ^b   Ivinson, Karen ^d   Heerwegh, Dirk ^c   Otsyula, Nekoye ^a   Oziemkowska, Maria ^b   Usuf, Effua Abigail ^c   Otieno, Allan ^a   Otieno, Kephas ^b   Leboulleux, Didier ^d   Leach, Amanda ^c   Oyieko, Janet ^a   Slutsker, Laurence ^b   Lievens, Marc ^c   Cowden, Jessica ^a   Lapierre, Didier ^c   Kariuki, Simon ^b   Ogutu, Bernhards ^a   Vekemans, Johan ^c   Hamel, Mary J ^b   more..

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c GSK   (Belgium)

^d PATH Malaria Vaccine Initiative   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; COTRIMOXAZOLE; LAMIVUDINE; LOPINAVIR; MALARIA VACCINE; NEVIRAPINE; RABIES VACCINE; RITONAVIR; VIRUS DNA; ZIDOVUDINE;

ABSCESS; AMEBIASIS; ANEMIA; ARTICLE; ASPIRATION PNEUMONIA; ATYPICAL MYCOBACTERIOSIS; BRONCHIOLITIS; CD4+ T LYMPHOCYTE; CELLULITIS; CHICKENPOX; CHILD; CLINICAL ASSESSMENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; CONVULSION; DEHYDRATION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; FEBRILE CONVULSION; FEMALE; FEVER; FOLLOW UP; GASTROENTERITIS; HAEMOPHILUS MENINGITIS; HELMINTHIASIS; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOKALEMIA; IMMUNOGENICITY; INFANT; INTENTION TO TREAT ANALYSIS; KENYA; KWASHIORKOR; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALARIA; MALE; MALNUTRITION; MEASLES; MORTALITY; MULTICENTER STUDY; OPPORTUNISTIC INFECTION; OROPHARYNX CANDIDIASIS; OTITIS MEDIA; OUTCOME ASSESSMENT; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL SEPSIS; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SALMONELLA SEPSIS; SEPSIS; STATISTICAL ANALYSIS; THRUSH; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS INFECTION; WORLD HEALTH ORGANIZATION; COMPLICATION; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; MALARIA, FALCIPARUM;

DOUBLE-BLIND METHOD; HIV; HIV INFECTIONS; HUMANS; INFANT; KENYA; MALARIA VACCINES; MALARIA, FALCIPARUM; RABIES VACCINES;

EID: 84990032623     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(16)30161-X     Document Type: Article

References (30)

1. 1 WHO. World Malaria Report 2015. http://www.who.int/malaria/publications/world-malaria-report-2015/report/en/ (accessed Feb 21, 2016).
2. 2 Greenwood, BM, Fidock, DA, Kyle, DE, et al. Malaria: progress, perils and prospects for eradication. J Clin Invest 118 (2008), 1266–1276.
3. 3 UNAIDS. Global Report on AIDS. http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Global_Report_2013_en_1.pdf, 2013 (accessed Oct 3, 2014).
4. 4 Cohen, J, Nussenzweig, V, Nussenzweig, R, Vekemans, J, Leach, A, From the circumsporozoite protein to the RTS,S/AS candidate vaccine. Hum Vaccin 6 (2010), 90–96.
5. 5 Casaresa, S, Brumeanub, TD, Richie, TL, The RTS, S malaria vaccine. Vaccine 28 (2010), 4880–4894.
6. 6 The RTS, S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386 (2015), 31–45.
7. 7 The RTS, S Clinical Trials Partnership. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 367 (2012), 2284–2295.
8. 8 The RTS, S Clinical Trials Partnership. First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. N Engl J Med 365 (2011), 1863–1875.
9. 9 European Medicines Agency. First malaria vaccine receives positive scientific opinion from EMA. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2015/07/WC500190447.pdf (accessed Feb 23, 2016).
10. 10 WHO. Malaria vaccine: WHO position paper-January 2016. Wkly Epidemiol Rec 91 (2016), 33–52.
11. 11 WHO. Malaria and HIV interactions and their implications for public health policy. Report of a Technical Consultation, 2004, World Health Organization, Geneva.
12. 12 Cuadros, DF, Branscum, AJ, Crowley, PH, HIV–malaria co-infection: effects of malaria on the prevalence of HIV in east sub-Saharan Africa. Int J Epidemiol 40 (2011), 931–939.
13. 13 Moss, WJ, Clements, CJ, Halsey, NA, Immunization of children at risk of infection with human immunodeficiency virus. Bull World Health Organ 81 (2003), 61–70.
14. 14 Kenya Ministry of Health. Annual Malaria Report July, 2012, to June, 2013. http://www.nmcp.or.ke/index.php/resource-centre/download-centre/category/5-surveillance-monitoring-and-evaluation (accessed April 9, 2015).
15. 15 Kohler, PK, Okanda, J, Kinuthia, J, et al. Community-based evaluation of PMTCT uptake in Nyanza Province, Kenya. PLoS One, 9, 2014, e110110.
16. 16 Thomas, TK, Masaba, R, Borkowf, CB, et al. Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding—the Kisumu breastfeeding study, Kenya: a clinical trial. PLoS Med, 8, 2011, e1001015.
17. 17 Bonhoeffer, J, Menkes, J, Gold, MS, et al. Generalized convulsive seizure as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine 22 (2004), 557–562.
18. 18 WHO. Verbal autopsy standards: ascertaining and attributing cause of death, 2007, World Health Organization, Geneva.
19. 19 Clement, F, Dewar, V, Van Braeckel, E, et al. Validation of an enzyme-linked immunosorbent assay for the quantification of human IgG directed against the repeat region of the circumsporozoite protein of the parasite Plasmodium falciparum. Malar J, 11, 2012, 384.
20. 20 Vickers, AJ, The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study. BMC Med Res Methodol, 1, 2001, 6.
21. 21 Vekemans, J, Guerra, Y, Lievens, M, et al. Pooled analysis of safety data from pediatric phase II RTS,S/AS malaria candidate vaccine trials. Hum Vaccin 7 (2011), 1309–1316.
22. 22 Brichacek, B, Swindells, S, Janoff, EN, Pirruccello, S, Stevenson, M, Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. J Infect Dis 174 (1996), 1191–1199.
23. 23 Gunthard, HF, Wong, JK, Spina, CA, et al. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J Infect Dis 181 (2000), 522–531.
24. 24 Cheeseman, SH, Davaro, RE, Ellison, RT 3rd, Hepatitis B vaccination and plasma HIV-1 RNA. N Engl J Med, 334, 1996, 1272.
25. 25 Geretti, AM, Brooks, G, Cameron, C, et al. British HIV Association guidelines on the use of vaccines in HIV-positive adults. http://www.bhiva.org/documents/Guidelines/Immunisation/consultation/BHIVA-Immunisation-Guidelines-2015-Consultation.pdf, 2015 (accessed March 9, 2016).
26. 26 Kim, HN, Harrington, RD, Crane, HM, Dhanireddy, S, Dellit, TH, Spach, DH, Hepatitis B vaccination in HIV-infected adults: current evidence, recommendations and practical considerations. Int J STD AIDS 20 (2009), 595–600.
27. 27 Kroon, FP, van Dissel, JT, de Jong, JC, Zwinderman, K, van Furth, R, Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine 18 (2000), 3040–3049.
28. 28 The RTS, S Clinical Trials Partnership. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med, 11, 2014, e1001685.
29. 29 Manyando, C, Njunju, EM, D'Alessandro, U, Van Geertruyden, JP, Safety and efficacy of co-trimoxazole for treatment and prevention of Plasmodium falciparum malaria: a systematic review. PLoS One, 8, 2013, e56916.
30. 30 Ockenhouse, CF, Regules, J, Tosh, D, et al. Ad35.CS.01-RTS,S/AS01 heterologous prime boost vaccine efficacy against sporozoite challenge in healthy malaria-naive adults. PLoS One, 10, 2015, e0131571.